Loading data for CTMX — first visit, this takes a few seconds.

CytomX Therapeutics, Inc. (CTMX)

NasdaqGS: CTMX · 即時價格 · USD

3.54

+0.18 (5.36%)

收盤價： Sep 02, 2026, 7:36 PM

提醒

Alert

股價、關鍵數字和最新消息，都在這一頁。

無可用資料

買價	2.48
市值	820M
營收 (ttm)	18.3M
淨利（ttm）	-82.7M
	2.14
	-0.57
	n/a
	-7.96
P/B (ttm)	2.72
P/S (ttm)	44.82
財報日期	Aug 7, 2025

賣價	4.27
成交量	1,204,504
20 日平均成交量	3,884,207
開盤價	3.32
前收盤價	3.36
當日區間	3.32 - 3.54
52 週範圍	1.90 - 8.21
分析師	n/a
目標價	n/a
股利	n/a
除息日	n/a

關於 CTMX

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increa...

[閱讀更多]

產業 Biotechnology

類股 Healthcare

IPO 日期 Oct 8, 2015

員工 69

證券交易所 NasdaqGS

股票代號 CTMX

網站 https://www.cytomx.com

完整的公司簡介

財務表現

CytomX Therapeutics 在 2025 年的營收為 76.2M，較前一年的 138.1M 減少 -44.82%。淨利為 -17.37M，較前期減少 -154.5%。

財務報表

財報驚奇

CytomX Therapeutics 已於 Aug 6, 2026 公布季度財報：

營收為 $1.42M 低於預期 $0, 年增 -92.40% 下滑.
每股盈餘為 -0.09 超出預期 0.01, 年增 -133.33% 下滑.

下次財報發布

CytomX Therapeutics, Inc. 的下次財報預計於 Aug 7, 2025, 收盤後。
分析師預估營收 ... 升級

價格為何變動

新聞動態

4 週前 · GuruFocus.com

CytomX Therapeutics Inc (CTMX) (Q2 2026) Earnings Call Highlights: Varetta M Advances Toward ...

Strong clinical progress and expanded Regeneron collaboration bolster CytomX's path forward despite revenue decline and safety considerations.

4 週前 · MarketBeat

CytomX Therapeutics Q2 Earnings Call Highlights

CytomX Therapeutics (NASDAQ:CTMX) said its second-quarter focus remained on advancing Varseta-M, an EpCAM-targeting antibody-drug conjugate being developed for metastatic colorectal cancer, while expa...

4 週前 · Zacks

CytomX Therapeutics (CTMX) Reports Q2 Loss, Lags Revenue Estimates

CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of +18.18% and -80.21%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

1 月前 · Zacks

CytomX Therapeutics (CTMX) Upgraded to Buy: Here's Why

CytomX Therapeutics (CTMX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

2 月前 · Insider Monkey

Is CytomX (CTMX) One of the Best Growth Stocks Under $30 to Buy Now?

CytomX Therapeutics Inc. (NASDAQ:CTMX) is one of the best growth stocks under $30 to buy now. On June 3, CytomX expanded its research collaboration with Regeneron to develop next-gen conditionally-act...

第 1 頁，共 2 頁

CytomX Therapeutics, Inc. (CTMX)